Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program
Status:
Completed
Trial end date:
2016-02-28
Target enrollment:
Participant gender:
Summary
This study is an early access program of 'Nexavar post-marketing surveillance (PMS) for renal
cell carcinoma (RCC) in Japan' which is a regulatory, local prospective and observational
study for patients with unresectable or advanced RCC under real-life practice conditions. The
objective of this study is to assess safety and effectiveness of Nexavar at some limited
sites which joined to clinical trial of Nexavar, before available of it in the market. The
enrollment period is 2 months, and patients who received Nexavar will be recruited and
followed one year since starting Nexavar administration. The data of this study will be
integrated into the Nexavar PMS and the data will not be analyzed and reported alone.